ENvue Medical Secures USPTO Allowance for Ultrasound-Boosted Cannabinoid Delivery Patent
FEED•ENvue Medical received a USPTO Notice of Allowance for Patent Application No. 17/025,969, covering its proprietary surface acoustic wave ultrasound-enhanced cannabinoid transdermal delivery system. The allowed claims grant broad IP protection for transdermal patch designs, portable SAW platforms and methods demonstrating synergistic absorption over patches alone.
1. Patent Notice of Allowance
On May 8, 2026, ENvue Medical announced receipt of a USPTO Notice of Allowance for U.S. Patent Application No. 17/025,969. This notice confirms that the application meets patentability criteria and clears the way for full grant of a novel drug delivery system.
2. Technology Scope and Claims
The allowed claims encompass combined SAW ultrasound and cannabinoid transdermal delivery, including various patch configurations, portable ultrasound-generating platforms and specific methods that enhance absorption compared to transdermal patches used alone. Broad protection covers multiple system components and delivery methods.
3. Therapeutic and Commercial Implications
Cannabinoid-based therapeutics are rapidly expanding in pain management, neurology, inflammation and chronic disease treatment. ENvue Medical’s SAW platform could improve drug administration efficacy and form the basis for strategic partnerships with pharmaceutical and biotech firms.
4. IP Portfolio Expansion and Growth Opportunities
This allowance marks ENvue’s entry into advanced therapeutic delivery applications beyond its feeding tube navigation business. The strengthened patent portfolio positions the company for future product development, licensing deals and diversification into non-invasive therapy markets.
